CD40LG and malaria: Additionally, in an RTS,S/AS0 vaccination trial conducted in Mozambique and Ghana, vaccinated infants (1.5 to 3 months) who had higher level of anti-α-gal IgM plasma antibodies were protected against clinical malaria over a one-year follow up compared to infants with low levels of IgM plasma antibody [20].